Presentation of EBV peptides by HLA-E, a non-classical MHC class I molecule engaging CD94/NKG2A (inhibitory receptor) or CD94/NKG2C (activating receptor) on NK cells and the TCR of cytotoxic CD8 T cells, was also investigated in MS patients (186). This evidence concerns the gene CD8A and myeloid sarcoma.